Anti–Epstein–Barr Virus BNLF2b for Mass Screening for Nasopharyngeal Cancer
Authors:
- Tingdong LiTLTingdong Li
- Fugui LiFLFugui Li
- Xiaoyi GuoXGXiaoyi Guo
- Congming HongCHCongming Hong
- Xia YuXYXia Yu
- Biaohua WuBWBiaohua Wu
- Shifeng LianSLShifeng Lian
- Liuwei SongLSLiuwei Song
- Jiabao TangJTJiabao Tang
- Shunhua WenSWShunhua Wen
- Kaimin GaoKGKaimin Gao
- Mengling HaoMHMengling Hao
Top Cited Papers
- 31 August 2023
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 389 (9) , 808-819
Abstract
Population screening of asymptomatic persons with Epstein-Barr virus (EBV) DNA or antibodies has improved the diagnosis of nasopharyngeal carcinoma and survival among affected persons. However, the positive predictive value of current screening strategies is unsatisfactory even in areas where nasopharyngeal carcinoma is endemic. We designed a peptide library representing highly ranked B-cell epitopes of EBV coding sequences to identify novel serologic biomarkers for nasopharyngeal carcinoma. After a retrospective case-control study, the performance of the novel biomarker anti-BNLF2b total antibody (P85-Ab) was validated through a large-scale prospective screening program and compared with that of the standard two-antibody-based screening method (EBV nuclear antigen 1 [EBNA1]-IgA and EBV-specific viral capsid antigen [VCA]-IgA). P85-Ab was the most promising biomarker for nasopharyngeal carcinoma screening, with high sensitivity (94.4%; 95% confidence interval [CI], 86.4 to 97.8) and specificity (99.6%; 95% CI, 97.8 to 99.9) in the retrospective case-control study. Among the 24,852 eligible participants in the prospective cohort, 47 cases of nasopharyngeal carcinoma (38 at an early stage) were identified. P85-Ab showed higher sensitivity than the two-antibody method (97.9% vs. 72.3%; ratio, 1.4 [95% CI, 1.1 to 1.6]), higher specificity (98.3% vs. 97.0%; ratio, 1.01 [95% CI, 1.01 to 1.02]), and a higher positive predictive value (10.0% vs. 4.3%; ratio, 2.3 [95% CI, 1.8 to 2.8]). The combination of P85-Ab and the two-antibody method markedly increased the positive predictive value to 44.6% (95% CI, 33.8 to 55.9), with sensitivity of 70.2% (95% CI, 56.0 to 81.4). Our results suggest that P85-Ab is a promising novel biomarker for nasopharyngeal carcinoma screening, with higher sensitivity, specificity, and positive predictive value than the standard two-antibody method. (Funded by the National Key Research and Development Program of China and others; ClinicalTrials.gov number, NCT04085900.).Keywords
Funding Information
- Fujian Provincial Department of Science and Technology (2020YZ015004, 2022L3080)
- Ministry of Education of the People’s Republic of China (20720220006, 20720220005)
- Ministry of Science and Technology of the People’s Republic of China (2020YFC1316900)
This publication has 28 references indexed in Scilit:
- Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in TaiwanClinical Cancer Research, 2018
- Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal CancerNew England Journal of Medicine, 2017
- Global trends in incidence and mortality of nasopharyngeal carcinomaCancer Letters, 2016
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- Circulating Epstein–Barr virus microRNAs miR‐BART7 and miR‐BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatmentInternational Journal of Cancer, 2014
- Two Epstein-Barr Virus-Related Serologic Antibody Tests in Nasopharyngeal Carcinoma Screening: Results From the Initial Phase of a Cluster Randomized Controlled Trial in Southern ChinaAmerican Journal of Epidemiology, 2012
- Two-Step Epstein-Barr Virus Immunoglobulin A Enzyme-Linked Immunosorbent Assay System for Serological Screening and Confirmation of Nasopharyngeal CarcinomaClinical and Vaccine Immunology, 2009
- Molecular Diversity of Epstein‐Barr Virus IgG and IgA Antibody Responses in Nasopharyngeal Carcinoma: A Comparison of Indonesian, Chinese, and European SubjectsThe Journal of Infectious Diseases, 2004
- A CACCC Box-like cis-Regulatory Element of the Epstein-Barr Virus ED-L2 Promoter Interacts with a Novel Transcriptional Factor in Tissue-specific Squamous EpitheliaJournal of Biological Chemistry, 1997
- Prospective studies on nasopharyngeal carcinoma in epstein‐barr virus IgA/VCA antibody‐positne persons in Wuzhou city, chinaInternational Journal of Cancer, 1985